Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Two-Year Case Into Six

The forged prescription carried the name of a doctor at a clinic that did not exist. That detail, buried in the Athletics Integrity Unit statement, is the first thing that holds. Ruti Aga, the 32-year-old Ethiopian marathoner, has been banned for six years. The ban is dated from 10 September, the day her provisional suspension began; the statement does not give the year. The case traces to a half marathon she won in China in March, where an in-competition sample returned methylprednisolone. In years of covering road racing, the first question in such cases is never about form. It is about paperwork. Here the paperwork broke first. Aga's record includes the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. She belongs to a generation in which Ethiopian women's marathon depth is so extreme that a 2:18–2:20 performer is not automatically selectable for a national team. The AIU statement gives no time, no splits and no field strength for the Chinese half marathon. Reading that race as proof of form would be wrong. The available fact is that she won it, which implies an elite field and in-competition testing. The raw sheet had two stories; I followed the one with a receipt. The receipt here is the AIU statement, and it is mostly procedure. The sanction arithmetic is simple: two years for presence, four years for tampering, six years in total. The two-year presence sanction is consistent with a Specified Substance finding where intent was not proven; four years is the standard tampering sanction. The panel rejected the no-significant-fault mitigation that could have reduced the presence period. Backdating to 10 September is procedural benefit, not a discount: provisional suspension time counts against the ban. Six years removes her from the 2028 Olympic cycle entirely. At 38, returning to an Ethiopian selection pool this deep, with a doping record, is close to impossible. A selection review is a paper trail with consequences, not a ceremony. Here the consequence is a stopped career clock. A technical correction is necessary. Several reports called methylprednisolone a prohibited steroid. That is imprecise. Methylprednisolone is a glucocorticoid, class S9 on the World Anti-Doping Agency Prohibited List; anabolic steroids sit in S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal routes. The case therefore hinged on route and timing, not on a claimed endurance boost. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. Out of competition, that treatment can be legal; residues in competition make it a violation. A road race's testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. A properly documented athlete with correct washout timing had a defence. The forged prescription destroyed it. The doctor was a family member with no medical registration, the clinic disowned the prescription, and the claim about an old prescription pad collapsed. Three independent verification failures. The case is about medical governance more than pharmacology. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners. Injured runners face strong incentives to mask pain because appearance fees and Major race cycles depend on availability. Glucocorticoids are the cheapest, most available tool for that. A credentialed team physician, a TUE process and proper record-keeping are the real safeguards. The AIU statement names only the family member; it does not say whether an agent or management was investigated. The Ethiopian federation is not quoted. China's label-race circuit combines large appearance-fee budgets, deep East African elite fields and AIU testing. That same tier is now a high-scrutiny zone. A six-year ban for a glucocorticoid looks severe, especially for a substance with no proven endurance benefit. Some will call it AIU rigour; others will call it disproportionate enforcement against African road runners. Both readings are easy. The weight of this case comes from the forged document. An athlete with genuine treatment records has no reason to manufacture a prescription. That question returns to the entourage. A CAS appeal is possible, typically within about 21 days of the reasoned decision, but a document-based tampering finding is hard to overturn. I trust the archive more than the highlight reel, especially when money moves. The next variables are the appeal, the disqualification scope for the March race and its prize money, and tighter document checks in Chinese label races. The 2026 Tokyo title is not automatically annulled absent a finding of earlier use; the AIU statement does not define the scope. The larger question is how the next injured marathoner reaches a real doctor instead of a forged pad.